Partnership accelerates the development of promising new immunotherapies
March 26, 2018
BOULDER, CO-ArcherDX, Inc. and Ambry Genetics® announced today a partnership wherein Ambry will provide biopharma sequencing services employing ArcherDX’s next-generation sequencing (NGS) tests.
Ambry Genetics will utilize Archer® Immunoverse™ and VariantPlex® NGS tests to provide large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics to biopharma customers.
The tests are based on ArcherDX’s patented Anchored Multiplex PCR (AMP™) technology and will target B- and T-cell receptor complementarity-determining regions to assess quantitative changes in the immune repertoire. The technology will also target CAR-T vectors to investigate the engineered T-cell repertoire over the course of autologous CAR-T cell manufacturing and treatment. Archer® tests will also map the diversity of CAR-T integration sites and estimate both the transduction efficiency and copy number of integration events. “The ability to characterize CAR T-cells at this resolution provides an unprecedented level of quality control to the T-cell engineering process,” states Dr. Phillip Gray, Vice President of Advanced Genomic Services at Ambry Genetics.
“Immunotherapy holds huge therapeutic potential, and we are very excited about this collaboration with Ambry Genetics to provide novel immune sequencing capabilities to biopharma partners in the immune-oncology space,” says Dr. Jason Myers, CEO of ArcherDX. Dr. Gray from Ambry further stated that “Immuno-oncology is the fastest growing segment within the pharma oncology field, and Ambry is excited to offer ArcherDX’s innovative technologies to accelerate the development of these promising new therapies.”